Xconomy | San Diego - Business + Technology in the Exponential Economy

Biotech, deals, Lupus

La Jolla Pharma Inks BioMarin Deal

Luke Timmerman 1/7/09

La Jolla Pharmaceutical (NASDAQ: LJPC) has formed a partnership to co-develop its experimental drug for lupus of the kidneys, Riquent, with Novato, CA-based BioMarin Pharmaceuticals (NASDAQ: BMRN). La Jolla will receive a $15 million upfront payment, and could stand to get $289 million in cash and equity from BioMarin if the drug reaches certain development goals. The medicine is in the final stage of clinical trials.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.


Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2009, Xconomy, Inc. XCONOMY is a registered service mark of Xconomy, Inc. All rights reserved.
Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.